All News

Adults with undiagnosed asthma or COPD who were randomly detected and assigned to specialist or usual care all had improved outcomes at 1 year, Canadian authors reported.

Which state has the lowest percentage of teen drug users? Or the highest percentage of adults with unmet drug-treatment needs? Answers from a new report, here.

Women with class 3 obesity before becoming pregnant have up to a 4.5-fold greater risk of composite maternal morbidity that includes preeclampsia, preterm delivery, DM.

DDW 2024. Offspring with both parents with overweight had a nearly 3-fold increased risk of MASLD in young adulthood, according to new data.

Your daily dose of the clinical news you may have missed.

Data presented at ACOG 2024 suggest SARS-CoV-2 infection early in pregnancy can lead to a higher likelihood of preeclampsia, as well as more severe disease.

Dupilumab reduced COPD exacerbations by 34% in adults with uncontrolled symptoms and evidence of T2 inflammation, and significantly improved lung function.

DDW 24. New research shows patients with MASLD and T2D who used GLP-1 agonists had a reduced risk of progression to cirrhosis and HCC vs non-users.

Your daily dose of the clinical news you may have missed.

ATS: The biologic shows promise in a range of people with COPD, particularly those with BEC levels of 150 cells/μL and greater, according to findings released at the 2024 ATS meeting.

The triple therapy cut risk of a first cardiopulmonary event by 20% vs dual therapy in addition to significantly reducing COPD exacerbations, PI Singh told Patient Care.

Men with diabetes had a greater risk of CVD, lower limb and kidney complications, and diabetic retinopathy compared to women with diabetes.

Your daily dose of the clinical news you may have missed.

The 2 phase 3 trials met all primary and secondary endpoints, showing statistically significant reduction in symptoms and sleep disturbance and improvement in quality of life.

In the phase 1b trial, treatment with once-weekly subcutaneous CT-388 led to a statistically significant mean placebo-adjusted weight loss of nearly 20%.

Your daily dose of the clinical news you may have missed.

Sipavibart met both dual primary endpoints in the SUPERNOVA phase 3 trial.

Safety and HbA1c reduction with efsitora alfa dosed once weekly was comparable to both daily insulin degludec and daily insulin glargine, announced Lilly.